6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $84M | -$171M | 0.0% | -212.9% | -$171M | $96M | $41M |
| 2024 | $89M | $8M | 0.0% | -3.5% | $13M | $0 | $51M |
| 2023 | $30000 | -$54M | 100.0% | -225066.7% | -$59M | — | $71M |
| 2022 | $1M | -$35M | 0.0% | -2698.8% | -$40M | — | $211M |
| 2021 | $6M | -$20M | 0.0% | -353.3% | -$18M | — | $60M |
| 2020 | — | -$33M | — | — | -$32M | — | $387M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $23M | -$61M | 0.0% | -265.2% | -$45M | $97M | $24M |
| Dec '25 | $28M | -$41M | 0.0% | -147.6% | -$43M | $96M | $41M |
| Sep '25 | $33M | -$51M | 0.0% | -163.7% | -$47M | $96M | $60M |
| Jun '25 | $16M | -$45M | 0.0% | -302.9% | -$40M | — | $52M |
| Mar '25 | $8M | -$34M | 0.0% | -466.3% | -$41M | — | $40M |
| Dec '24 | $87M | $50M | 0.0% | 54.5% | $42M | $0 | $51M |
| Sep '24 | $2M | -$19M | 0.0% | -1051.6% | -$15M | — | $40M |
| Jun '24 | $500000 | -$13M | 0.0% | -3068.0% | -$7M | — | $37M |
| Mar '24 | $0 | -$10M | — | — | -$7M | — | $56M |
| Dec '23 | $0 | -$7M | — | — | -$17M | — | $71M |
| Sep '23 | $0 | -$15M | — | — | -$13M | — | $61M |
| Jun '23 | $10000 | -$17M | 0.0% | -206030.0% | -$17M | — | $119M |
| Mar '23 | $20000 | -$15M | 0.0% | -93565.0% | -$13M | — | $88M |
| Dec '22 | $0 | -$14M | — | — | -$21M | — | $211M |
| Sep '22 | $189000 | -$7M | 0.0% | -3507.9% | -$6M | — | $203M |
| Jun '22 | $464000 | -$6M | 0.0% | -1367.2% | -$7M | — | $219M |
| Mar '22 | $663000 | -$7M | 0.0% | -1070.7% | -$7M | — | $234M |
| Dec '21 | — | $46M | — | — | $29M | — | $60M |
| Sep '21 | — | -$23M | — | — | -$19M | — | $301M |
| Jun '21 | — | -$24M | — | — | -$15M | — | $360M |
How the market has priced SPRY against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Ars Pharmaceuticals, Inc.'s revenue has grown 97.8% per year. These are computed facts, not advice.
As of FY2025, Ars Pharmaceuticals, Inc. reported $96M of total debt against $41M of cash.
In FY2025, gross margin was —, operating margin -212.9%, and net margin -203.3%.
As of Jun '26, Ars Pharmaceuticals, Inc. traded at a price-to-earnings ratio of about 118.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.